Xenon Pharmaceuticals Pauses Drug Trial, Sending Shares Down
Shares of Xenon Pharmaceuticals (XENE) plummeted after the company announced a pause in new patient enrollment for clinical trials evaluating azetukalner as a treatment for major depressive disorder. The decision followed reports of adverse neuropsychiatric side effects during monitoring, raising regulatory concerns and delaying potential expansion beyond its epilepsy indication. The stock is now trading nearly 40% below its year-to-date high with the relative strength index (RSI) signaling extremely oversold conditions. While azetukalner's core late-stage epilepsy program remains on track, safety issues in psychiatric trials could limit peak market potential and introduce uncertainty for investors. Despite this setback, Xenon maintains a strong balance sheet and continues to receive positive analyst ratings. RBC Capital Markets lowered its price target but still rates the stock as
Tickers: $XENE
Topics: biopharmaceutical drug development neuropsychiatric side effects stock decline